S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.65 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.65 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.65 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.39 (+0.42%)
META   502.32 (+2.49%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.65 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.78 (+0.52%)
AMD   202.64 (+5.25%)
BABA   74.62 (+0.80%)
T   16.98 (+0.30%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.65 (+1.12%)
DIS   111.95 (+0.33%)
AMC   4.36 (+0.93%)
PFE   26.59 (+0.11%)
PYPL   60.54 (+0.33%)
XOM   105.84 (+1.26%)
NASDAQ:MGNX

MacroGenics (MGNX) Stock Price, News & Analysis

$19.06
+1.12 (+6.24%)
(As of 04:00 PM ET)
Today's Range
$18.06
$19.39
50-Day Range
$9.62
$18.30
52-Week Range
$4.29
$19.39
Volume
2.00 million shs
Average Volume
1.22 million shs
Market Capitalization
$1.18 billion
P/E Ratio
23.83
Dividend Yield
N/A
Price Target
$15.29

MacroGenics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
19.9% Downside
$15.29 Price Target
Short Interest
Healthy
10.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
0.50mentions of MacroGenics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$827,498 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.73) to ($1.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.41 out of 5 stars

Medical Sector

284th out of 957 stocks

Pharmaceutical Preparations Industry

132nd out of 440 stocks


MGNX stock logo

About MacroGenics Stock (NASDAQ:MGNX)

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MGNX Stock Price History

MGNX Stock News Headlines

MacroGenics (MGNX) to Release Quarterly Earnings on Thursday
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
MGNX Dec 2024 22.500 put
MacroGenics: Trying To Build A Better Everything
Decoding 4 Analyst Evaluations For Macrogenics
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
MGNX Feb 2024 15.000 put
MGNX Mar 2024 10.000 put
MGNX Dec 2024 22.500 call
Demystifying Macrogenics: Insights From 5 Analyst Reviews
MGNX Dec 2024 10.000 call
MacroGenics gains as Citi upgrades to Buy
Citi gets more bullish on MacroGenics, upgrades shares
Forecasting The Future: 4 Analyst Projections For Macrogenics
Guggenheim Upgrades Macrogenics (MGNX)
MacroGenics (MGNX) Q3 2023 Earnings Call Transcript
See More Headlines
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/01/2024
Next Earnings (Confirmed)
3/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MGNX
Employees
357
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$15.29
High Stock Price Target
$23.00
Low Stock Price Target
$12.00
Potential Upside/Downside
-14.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-119,760,000.00
Pretax Margin
41.13%

Debt

Sales & Book Value

Annual Sales
$119.21 million
Book Value
$2.31 per share

Miscellaneous

Free Float
55,826,000
Market Cap
$1.11 billion
Optionable
Optionable
Beta
2.16

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Scott Koenig M.D. (Age 72)
    Ph.D., President, CEO & Director
    Comp: $1.06M
  • Mr. James  KarrelsMr. James Karrels (Age 57)
    Senior VP, CFO & Corporate Secretary
    Comp: $626.83k
  • Mr. Eric Blasius Risser (Age 51)
    Chief Operating Officer
    Comp: $651.36k
  • Dr. Thomas M. Spitznagel Ph.D. (Age 57)
    Senior Vice President of Technical Operations
    Comp: $550.97k
  • Dr. Ezio Bonvini (Age 70)
    Senior VP of Research & Chief Scientific Officer
    Comp: $612.21k
  • Mr. Jeffrey Stuart Peters (Age 53)
    Senior VP, General Counsel & Corporate Compliance Officer
  • Dr. Stephen L. Eck M.D. (Age 69)
    Ph.D., Senior VP of Clinical Development & Chief Medical Officer
    Comp: $577.62k
  • Ms. Lynn Cilinski (Age 66)
    VP, Controller & Treasurer














MGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MGNX shares.
View MGNX analyst ratings
or view top-rated stocks.

What is MacroGenics' stock price target for 2024?

7 brokerages have issued 12-month price targets for MacroGenics' stock. Their MGNX share price targets range from $12.00 to $23.00. On average, they expect the company's stock price to reach $15.29 in the next twelve months. This suggests that the stock has a possible downside of 19.9%.
View analysts price targets for MGNX
or view top-rated stocks among Wall Street analysts.

How have MGNX shares performed in 2024?

MacroGenics' stock was trading at $9.62 at the start of the year. Since then, MGNX shares have increased by 98.3% and is now trading at $19.08.
View the best growth stocks for 2024 here
.

Are investors shorting MacroGenics?

MacroGenics saw a decrease in short interest in February. As of February 15th, there was short interest totaling 6,380,000 shares, a decrease of 23.5% from the January 31st total of 8,340,000 shares. Based on an average daily trading volume, of 939,800 shares, the short-interest ratio is presently 6.8 days. Approximately 11.0% of the shares of the company are short sold.
View MacroGenics' Short Interest
.

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our MGNX earnings forecast
.

How can I listen to MacroGenics' earnings call?

MacroGenics will be holding an earnings conference call on Thursday, March 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) released its quarterly earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.23. The biopharmaceutical company had revenue of $15.66 million for the quarter, compared to analysts' expectations of $39.56 million. MacroGenics had a net margin of 41.13% and a negative trailing twelve-month return on equity of 51.83%. During the same period in the previous year, the firm earned ($0.66) EPS.

What ETF holds MacroGenics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 221,160 shares of MGNX stock, representing 1.03% of its portfolio.

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?
Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bellevue Group AG (16.05%), Armistice Capital LLC (7.37%), Vanguard Group Inc. (6.95%), Frazier Life Sciences Management L.P. (3.87%), Wasatch Advisors LP (2.09%) and Dimensional Fund Advisors LP (1.96%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends
.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MGNX) was last updated on 3/1/2024 by MarketBeat.com Staff